No complete clinical trials investigating CD19-chimeric antigen receptor (CAR) T cells for acute lymphoblastic leukaemia (ALL) have been published. express a CD19-CAR incorporating an anti-CD19 single-chain variable fragment plus TCR zeta and CD28 signalling domains. All patients received fludarabine and cyclophosphamide before a single infusion of CD19-CAR T cells. Using a standard 3 + 3 design to establish the maximum tolerated dose, patients received either 1 106 CAR-transduced T cells per kg (dose 1), 3 106 CAR-transduced T cells per kg (dose 2), BAX or the entire CAR T-cell product if sufficient numbers of cells to meet the assigned dose were not generated. After the dose-escalation phase, an growth cohort was treated at the maximum tolerated dose. The trial is usually registered with ClinicalTrials.gov, number “type”:”clinical-trial”,”attrs”:”text”:”NCT01593696″,”term_id”:”NCT01593696″NCT01593696. Findings Between July 2, 2012, and June 20, 2014, 21 patients (including eight who had previously undergone allogeneic haematopoietic stem-cell transplantation) were enrolled and infused with CD19-CAR T cells. 19 received the prescribed dose of CD19-CAR T cells, whereas the assigned dose concentration could not be generated for two patients (90% feasible). All patients enrolled were assessed for response. The maximum tolerated dose was defined as 1 106 CD19-CAR T cells per kg. All toxicities were fully reversible, with the most TAK-733 severe being grade 4 TAK-733 cytokine release syndrome that occurred in three (14%) of 21 patients (95% CI 30C363). The most common non-haematological grade 3 adverse events were fever (nine [43%] of 21 patients), hypokalaemia (nine [43%] of 21 patients), fever and neutropenia (eight [38%] of 21 patients), and cytokine release syndrome (three [14%) of 21 patients). Interpretation CD19-CAR T cell therapy is usually feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia. All toxicities were reversible and prolonged B-cell aplasia did not occur. Funding National Institutes of Health Intramural funds and St Baldricks Foundation. Introduction B-precursor acute lymphoblastic leukaemia (B-ALL) is TAK-733 the most common malignancy in childhood. Newly diagnosed children have about 90% survival, but remedy needs pro longed therapy with substantial short-term and long-term toxicities.1,2 Adults TAK-733 with B-ALL have lower survival rates, partly because of a high frequency of subtypes with less chemosensitivity.3,4 Irrespective of age, patients with primary or recurrent refractory B-ALL who do not have complete remission negative for minimum residual disease (MRD) with cytotoxic chemotherapy have dismal survival rates of less than 10%, and outcomes for these patients have not improved substantially in the last two decades.5C7 Chimeric antigen receptors (CARs) incorporate an antigen recognition sequence, such as a single-chain variable fragment (scFv) of a monoclonal antibody, with intracellular signalling domains that activate the T cell.8 Although several case series have reported antitumour effects of autologous CD19-directed CAR T cells in patients with B-cell lymphoma,9,10 chronic lymphocytic leukaemia,11,12 and B-ALL,12C15 results of an intention-to-treat protocol of sequentially enrolled patients treated with a consistent regimen has not been reported. In this phase 1 trial we define feasibility, toxicity, maximum tolerated dose, response rate, and biological correlates of response in 21 consecutively enrolled children and young adults with refractory B-cell malignancies treated with CD19-CAR T cells. Methods Study design and participants We did an open-label, phase 1 dose-escalation study of CD19-CAR T cells in children and young adults with ALL or non-Hodgkin lymphoma. Patients were screened and treated in the Pediatric Oncology Branch of the National Malignancy Institute (NCI) at the Clinical Center of the US National Institutes of Health. Data are presented until July 18, 2014, and responding patients continue to be followed up for TAK-733 survival, relapse, and as mandated by the US Food and Drug Administration (FDA),16 which requires 15 years of follow-up. Eligible patients were aged 1C30 years with CD19+B-ALL or non-Hodgkin lymphoma, relapsed or refractory to standard therapy plus at least one salvage regimen. Eligibility required measurable disease, adequate performance status, and organ function. Previous recipients of allogeneic haematopoietic stem-cell transplantation (HSCT) were eligible if more than 100 days post-transplant, without evidence of graft versus host disease (GVHD), and did not require immunosuppression. Patients with no detectable.